Orphan Drugs: Where have we been; Where are we now; Where are we going Marlene E. Haffner, MD, MPH Haffner Associates, LLC 11 October,

Slides:



Advertisements
Similar presentations
Patients’ Perspective on HTA and Off-label use David Head MBA Chief Executive RP Fighting Blindness 25th Annual EuroMeeting 4-6 March 2013 RAI, Amsterdam.
Advertisements

Data Monitoring Models and Adaptive Designs: Some Regulatory Experiences Sue-Jane Wang, Ph.D. Associate Director for Adaptive Design and Pharmacogenomics,
Rare Diseases and FDASIA
Marlene E. Haffner, MD, MPH CEO, Haffner Associates, LLC Orphan Drugs Summit 2012 Thursday, 27 th September 2012.
Office of Orphan Products Development (OOPD) Gayatri R. Rao, M.D., J.D. Acting Director NORD Corporate Council May 15, 2012.
Regulatory Requirements for Orphan Drugs Delivery Dr. Basavaraj K. Nanjwade M.Pharm., Ph.D Professor of Pharmaceutics KLE University, Belgaum, India
1 1 PDUFA & FDA Legislation FDA Regulatory & Compliance Symposium August 2006 Marc Wilenzick, Moderator for Panel: Dan Carpenter, Harvard Dept. of Government.
Haffner Associates, LLC1 Orphan Drugs – 2011 What’s Happening? Women in BIO Marlene E. Haffner, MD, MPH Office 301.
Good Clinical Practice GCP
I am a Disease: Where is my Drug?! Dalhousie University January 20, 2011 Marlene E. Haffner, MD, MPH 1.
Obtaining Orphan Product Designation Challenges and pitfalls Marlene E. Haffner, MD, MPH President and CEO Haffner Associates, LLC
Let’s talk about Orphan Drugs Critical Path Institute February 15, 2011 Marlene E. Haffner, MD, MPH 1.
Genetic Diseases of Children The Role of Orphan Drugs Marlene E. Haffner, MD, MPH 9 March
FDA’s Biosimilars Guidance -- Legal and Regulatory Considerations James S. Cohen, Esq. McDermott Will & Emery DIA Webinar April 10, 2012.
Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug.
Introduction to Drug Rediscovery John Lisman Attorney-at-law Lisman Legal Life sciences Insert your logo in this area then delete this text box.
Humanitarian Use Devices September 23, 2011 Theodore Stevens, MS, RAC Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and.
Wisconsin’s Challenges in Health Care Access and Cost: A Look at the Numbers March 22, 2006 Donna Friedsam, MPH Associate Director for Health Policy University.
How to audit the role of the vendor in the conduct of outsourced studies Kristel Van de Voorde Director Global Quality Regulatory Compliance Bristol-Myers.
Presenter Name Title Organization Twitter Handle Insert your logo here, then delete text.
The Power of the Rare Disease Community… Diane Dorman Vice President, Public Policy National Organization for Rare Disorders (NORD) 1 st International.
ICORD 2009: Inching towards Integration--- the NIH and FDA seek IOM Input on a National Rare Disease Policy Timothy Cote, MD MPH Director, Office of Orphan.
Click to add Presentation Title Arial 32, 5 line max title space line 3, title space line 4, title space line 5 Presenter Title Organization Insert your.
1 Optimal Strategies for Preparing Integrated and Clinical Summaries for a New Drug Application: Making it Work Under Any Circumstance Lisa A. Pierchala,
PDUFA Needs to be More Orphan-Friendly Diane Edquist Dorman Vice President, Public Policy National Organization for Rare Disorder (NORD)
FDA Office of Orphan Products Development
Intellectual Property Legal Implications. What is Intellectual Property? The product of creativity and intellectual endeavour Intellectual Property Rights.
 Treats a population of < 200,000 in the US  Same review and development standards as for a non- orphan product  Numbers of patients in clinical trials.
Bayesian approach to equivalence study of medical device 1 1.
Initiatives Drive Pediatric Drug Development January 30, 2002.
FDA Risk Communication Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee February 28, 2008.
How to successfully Implement and Leverage the Regulatory Intelligence Function Marianne Koehne EU RI Network Group; Global RI Manager Boehringer Ingelheim.
Making Comments Count for High-Impact Regulations and Guidelines in the US Virginia (Ginny) Beakes-Read Executive Director, Global Regulatory Policy and.
Strategic Analyses and Interpretation: Regulatory Intelligence for Decision Making Amy N. Grant Director, Regulatory Strategy & Science ViroPharma Incorporated.
Good Laboratory Practices and Inspection Readiness Paul Swidersky President/Sr. Consultant Quality Associates, Inc.
Meredith Brown-Tuttle, RAC Director APT Pharmaceuticals, Inc.
DIA ERS SIAC IND CMC eCTD Submissions Part II – IND to NDA
Process-based Metadata From a DIA Presentation: eTMF – Migrating from Paper Trial Master Files to Electronic Eldin Rammell, Managing Director, Rammell.
ICORD 2006 Kerstin Westermark Md, PhD, Assoc. prof. COMP Chairperson.
Experiences from building a lessons- learned database for regulatory interactions Åsa Rembratt Sr Reg Intelligence Manager Novo Nordisk A/S 26th Annual.
Group Sequential Tests for Delayed Responses Christopher Jennison Department of Mathematical Sciences University of Bath Lisa Hampson Department of Mathematics.
Making Comments Count for High-Impact Regulations and Guidelines in Canada, EU, Japan, and US Chairperson: Amy N. Grant Director, Regulatory Strategy &
Technology Transfer Office
Gabor Fari Life Sciences Solution Strategist Microsoft Corporation
University of Colorado Trademarks
- A “Portable” Implementation
Mutagenic Impurities: Guidances Update w/ CMC Perspectives
Presenter Title Organization
Track 11 Symposium 27 June :30 – 3:00 PM
Us Healthcare System.
Clinical Trial Disclosure:
Perspective on GCP Warning Letters
Implementing a Successful Corrective and Preventative Action Program
Molly Butler Auditor II Quality Associates, Inc.
Interactive Session: Presentation of Scenarios and Q&A
Community-Based and Cluster-Randomized Studies –‘Pragmatic’ Approaches for Life Cycle Evidence? Florian Eichmann, PhD Principal Scientific Affairs and.
FirstPoint and FirstDoc Application of the DIA EDM Reference Model
Presenter Name Title Organization.
1 Topic Title First slide 2 line 3 line 4 line
1 Topic Title First slide 2 line 3 line 4 line
Presenter Name Title Organization.
Suzanne M. Sensabaugh, MS, MBA
Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug.
1 Session Title 2 line 3 line 4 line
Effectiveness Marlene Haffner, MD MPH Haffner Associates, LLC
1 Session Title 2 line 3 line 4 line
1 Topic Title First slide 2 line 3 line 4 line
1 Topic Title First slide 2 line 3 line 4 line
William W. Gregory for the CIOMS MLG Exploratory Team Pfizer Inc
Advocacy 101 Kristen Angell, Associate Director of Advocacy
Presentation transcript:

Orphan Drugs: Where have we been; Where are we now; Where are we going Marlene E. Haffner, MD, MPH Haffner Associates, LLC 11 October, 2011

The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. (“DIA”), its directors, officers, employees, volunteers, members, chapters, councils, Special Interest Area Communities or affiliates, or any organization with which the presenter is employed or affiliated. These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, DIA and DIA logo are registered trademarks or trademarks of Drug Information Association Inc. All other trademarks are the property of their respective owners. 2www.diahome.orgDrug Information Association

Abbey Myers was concerned for – her and other children who could not obtain needed treatments for their disease AND – Hell hath no fury as woman scorned - William Congreve 1697 Marian Finkel, MD – Report “Significant Drugs of Liimited Commercial Value” – Tenets of the current US Orphan Drug Act were born – Laid out incentives including Exclusivity Protocol Assistance Grant Support Tax Incentives Lack of Profitability In the beginning…. Drug Information Association

Success was not immediate - Need to amend profitability statement – 1984; add prevalence 1986: 100 th designation AZT approved for a “new disease” HIV AIDS – 1986 Growth Hormone – what is the same and what is a different drug Concern about cost of orphan products – with growth hormone and AIDS drugs 1988 amendments – must be designated prior to submitting NDA Drug Information Association

Companies began to build around the Orphan Drug Act - Genentech, Enzon, Genzyme, BioMarin - Big Pharma not interested except by happenstance - Some of the new companies became both large and profitable Other countries become interested and pass their on legislation/regulations - Japan – Australia-1998 – and then EU, Taiwan, Singapore, and more Drug Information Association

Horse Races – if the population is big enough; the possibility of a horse race may exist – Digibind vs Digidote – Erythropoietins – Two Factor IX’s – Fabry’s disease – Pneumocystis drugs Regulations published – 1992 – Codified same/different – Not much else that was new Drug Information Association

Biotech becomes increasingly important An increasing number of orphan diseases described – more than 7000 on NIH list NIH Office of Rare Diseases and Research established by law (had already existed in fact) Pediatrics issues increasingly addressed Human Genome project New drugs for diabetes, hypertension, harder to find Realization that not all rare diseases are “that” rare – Oncology and Metabolic diseases very important Then - - Drug Information Association

Passage of PDUFA 2 – establishes waiver of Orphan drugs from user fees for initial reviews > $1.5 million Numbers of designations increase dramatically “Medically plausible” comes to the fore and is still being defined IOM committee studies issues of rare disease research Establishment of Office of Orphan Drugs in the Office of New Drugs/CDER Brownback Brown amendment – 2009 CDER establishes focus on orphan drug review Drug Information Association

Make Mine Rare By Megan Scudellari | August 1, 2011 With mounting interest from biotechs, Big Pharma, and the federal government, research on rare diseases is burgeoning Researchers at the Basel, Switzerland, branch of the Novartis Institutes for BioMedical Research develop therapies for rare diseases,…business is booming. Multiple Articles in popular and scientific Press Drug Information Association

Designations dramatically increase in last 4 years Creating Hope Act - rare Pediatric Diseases NORD petitions for FDA Policy Statement o Orphan Drug Review – Acknowledging that rare diseases have smaller populations with specific issue of drug development – Requests training for reviewers NIH establishes TRND Multiple consortia funded through NIH Office of Rare Disease Research Drug Information Association

Companies investing in orphan product research are multinational Consumer groups are ever more educated and active The human Genome has given rise to better understanding of many diseases – particularly inborn errors of metabolism EU COMP and FDA OOPD having regular discussions to better “harmonize” The World is a Smaller place Drug Information Association

Better understanding of surrogate and biomarkers in the study of rare diseases What are the challenges of small population studies Safety will remain a significant issue with small populations – REMS are exensive Biotech drugs serving a small population (economies of scale) will remain expensive – but must consider benefit risk Drug Information Association And yet to be done -

The future is Bright CDER and OOPD continue to coordinate Multiple international groups working together on behalf on patients with rare diseases – ICORD, IRDiRC Better understanding in CDER of the review process – consistency OOPD to continue outreach Drug Information Association

THANK YOU! ? Drug Information Association

Drug Information Association

16www.diahome.org Drug Information Association In the beginning…

Orphan 17www.diahome.org Drug Information Association

Orphan 18www.diahome.org Drug Information Association